

CytomX Therapeutics, Inc.
151 Oyster Point Blvd., Suite 400
South San Francisco, CA 94080

August 16, 2021

VIA EDGAR

Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549

Attention: Deanna Virginio

Re: CytomX Therapeutics, Inc.
Registration Statement on Form S-3 (Registration No. 333-258510)

Ladies and Gentlemen:

In accordance with Rule 461 of Regulation C of the General Rules and Regulations under the Securities Act of 1933, as amended, we hereby request acceleration by the Securities and Exchange Commission of the effective date of the above-referenced Registration Statement on Form S-3 (the "Registration Statement") of CytomX Therapeutics, Inc. We respectfully request that the Registration Statement become effective as of 4:00 p.m., Washington, D.C. time, on August 18, 2021, or as soon as practicable thereafter.

Thank you for your assistance in this matter.

Very truly yours,

CytomX Therapeutics, Inc.

By: /s/ Lloyd A. Rowland

Lloyd A. Rowland

Senior Vice President and General Counsel

CC: Sean A. McCarthy, CytomX Therapeutics, Inc.
Carlos Campoy, CytomX Therapeutics, Inc.
Mark V. Roeder, Latham & Watkins LLP